An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management with robust cardiovascular benefits.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was developed by Novo Nordisk and approved by the FDA for type 2 diabetes management (Ozempic, 2017) and chronic weight management (Wegovy, 2021). It is a 94% sequence homolog of native GLP-1 with two key modifications: a C18 fatty diacid chain attached to lysine at position 26 (enabling albumin binding and extending half-life to approximately 7 days), and an Aib substitution at position 8 (protecting against DPP-4 degradation). The STEP 1 trial demonstrated a mean weight loss of 14.9% over 68 weeks, and the SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events in non-diabetic obese patients, establishing semaglutide as a landmark agent in both metabolic and cardiovascular medicine.
* Benefits based on preclinical/animal research unless otherwise noted.
“An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management with robust cardiovascular benefits.”
Semaglutide binds to and activates GLP-1 receptors (GLP-1R), which are G protein-coupled receptors expressed in the pancreas, brain, heart, kidneys, and gastrointestinal tract. In the pancreas, GLP-1R activation stimulates glucose-dependent insulin secretion from beta cells and suppresses glucagon from alpha cells, improving glycemic control without causing hypoglycemia at normal glucose levels. In the hypothalamus and brainstem (particularly the arcuate nucleus and area postrema), GLP-1R activation reduces appetite and food intake by modulating neuropeptide Y (NPY), AgRP, and POMC signaling. Semaglutide also slows gastric emptying, prolonging satiety after meals. Its cardiovascular benefits appear to involve direct anti-inflammatory effects on arterial walls, reduction of oxidative stress, and improvement of endothelial function through GLP-1R signaling in cardiac and vascular tissue.
Protocol Notes: Start at 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then increase by 0.5 mg every 4 weeks as tolerated. Maximum dose for weight management is 2.4 mg weekly.
Available as pre-filled pens. Compounded: per pharmacy instructions.
When sourcing Semaglutide for research purposes, the following quality benchmarks should be verified before use.
Refrigerate (2–8°C). Room temperature up to 56 days after first use. Do not freeze.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Strong Evidence — Multiple randomized controlled trials with high confidence in efficacy and safety data.
Peptides commonly used alongside Semaglutide for synergistic effects.
Amylin Receptor Agonist
A long-acting amylin analog that complements GLP-1 therapy for superior weight loss and metabolic control.
Learn More: CagrilintideGIP/GLP-1 Dual Receptor Agonist
The first dual GIP/GLP-1 receptor agonist, demonstrating superior weight loss outcomes compared to GLP-1 monotherapy.
Learn More: Tirzepatide